With nasal delivery systems offering faster absorption and non-invasive administration, they are becoming a cornerstone of modern therapeutics. Whether for nose-to-brain delivery or emergency use, nasal delivery is opening a new era of more efficient drug and vaccine administration with life-saving potential. However, challenges in biologics formulation, along with renewed interest from major pharmaceutical companies and investors, raise questions about how other companies are addressing development obstacles and the most effective strategies to secure funding.

Dedicated to navigating investment pathways for nasal companies, boosting drug bioavailability in target regions, optimizing translational modelling, and determining the efficacy of delivery devices, the 3rd Nasal Formulation & Delivery Summit united biotechs and innovative start-ups to share case studies and best practices in optimizing nasal drug delivery across different therapeutic areas.